43 related articles for article (PubMed ID: 19533437)
1. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.
Sato R; Gomez Rey G; Nelson S; Pinsky B
Appl Health Econ Health Policy; 2013 Jun; 11(3):251-8. PubMed ID: 23605251
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults.
Polsky D; Bonafede M; Suaya JA
BMC Health Serv Res; 2012 Oct; 12():379. PubMed ID: 23113880
[TBL] [Abstract][Full Text] [Related]
3. Direct costs of neonatal infection acquired in the community in full-term newborns and low risk at birth, Cundinamarca, Colombia.
Agudelo SI; Molina CF; Gamboa ÓA; Suárez JD
Biomedica; 2021 Mar; 41(1):87-98. PubMed ID: 33761192
[TBL] [Abstract][Full Text] [Related]
4. Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia.
Akyıl FT; Hazar A; Erdem İ; Öneş CP; Yalçınsoy M; Irmak İ; Kasapoğlu US
Turk Thorac J; 2015 Jul; 16(3):107-113. PubMed ID: 29404087
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Patients with Community-Acquired Pneumonia Who Did and Did not Receive Treatment in Accordance with the 2009 Pneumonia Guideline of Turkish Thoracic Society.
Soylar ÖK; Kılınç O; Ellidokuz H
Turk Thorac J; 2015 Apr; 16(2):64-67. PubMed ID: 29404080
[TBL] [Abstract][Full Text] [Related]
6. Burden of community-acquired pneumonia in adults over 18 y of age.
Kosar F; Alici DE; Hacibedel B; Arpınar Yigitbas B; Golabi P; Cuhadaroglu C
Hum Vaccin Immunother; 2017 Jul; 13(7):1673-1680. PubMed ID: 28281915
[TBL] [Abstract][Full Text] [Related]
7. Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain).
Sicras-Mainar A; Ibáñez-Nolla J; Cifuentes I; Guijarro P; Navarro-Artieda R; Aguilar L
BMC Infect Dis; 2012 Nov; 12():283. PubMed ID: 23114195
[TBL] [Abstract][Full Text] [Related]
8. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?
Nathwani D; Rubinstein E; Barlow G; Davey P
Clin Infect Dis; 2001 Mar; 32(5):728-41. PubMed ID: 11229840
[TBL] [Abstract][Full Text] [Related]
9. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
10. Community acquired pneumonia and direct hospital cost.
Doruk S; Tertemiz KC; Kömüs N; Uçan ES; Kilinç O; Sevinç C
Tuberk Toraks; 2009; 57(1):48-55. PubMed ID: 19533437
[TBL] [Abstract][Full Text] [Related]
11. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
[TBL] [Abstract][Full Text] [Related]
12. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
13. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
14. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
